Who is sponsoring NCT05274334?

NCT05274334 is sponsored by University Children's Hospital Basel.

What drugs are being tested in NCT05274334?

Interventions in NCT05274334: Assessment of de novo lipogenesis non-invasively in exhaled breath.

What condition does NCT05274334 study?

NCT05274334 studies De Novo Lipogenesis (DNL).

Is NCT05274334 still recruiting?

NCT05274334 is currently completed. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT05274334: D2OBREATH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis

Completed NA Last updated 4 November 2022

What this trial tests

NA trial testing Assessment of de novo lipogenesis non-invasively in exhaled breath in De Novo Lipogenesis (DNL) in 5 participants. Completed in 30 September 2022.

Timeline

11 May 2022

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	University Children's Hospital Basel
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	5
Start date	11 May 2022
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Assessment of de novo lipogenesis non-invasively in exhaled breath

Conditions studied

De Novo Lipogenesis (DNL) — all drugs for De Novo Lipogenesis (DNL) →

Sponsor

University Children's Hospital Basel

Who can join

18 and older, any sex, with De Novo Lipogenesis (DNL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proof of concept- study is to measure de novo lipogenesis (DNL) non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Children's Hospital Basel trials

Trials by the same sponsor.

NCT06861530 — A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymp · recruiting
NCT05856812 — BOrrelia BUrgdorferi IN Children and Adolescents · completed
NCT05477810 — Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg · EARLY_PHASE1 · completed
NCT04812483 — Immunomodulation With Eltrombopag in ITP · Phase 2 · completed
NCT04956718 — Breath Metabolomics of Placebo Effects, a Pilot Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05274334 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Children's Hospital Basel
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05274334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing